Sarcoma is referred to as a type of cancer that originates from the mesenchymal transformed cells. Fibrosarcoma is a rare malignancy, which is characterized by anaplastic undifferentiated spindle cells or proliferating immature fibroblasts in a storiform appearance. The disease arises from the fibrous tissue of bones such as the tibia, the femur, or the mandible. The tumor may be categorized based on differentiation degree into low-grade malignancy, intermediate malignancy, and anaplastic malignancy. Prevalence of fibrosarcoma is higher among men than women. As per the National Cancer Institute (NCI), only 5% of bone sarcomas are found to be fibrosarcoma. According to database of the Surveillance, Epidemiology & End Results (SEER), the rate of incidence of bone joint sarcomas was 0.9 per 100,000 people between 2000 and 2004. Based on type, fibrosarcoma can be divided into primary medullary fibrosarcoma, primary surface fibrosarcoma, secondary fibrosarcoma, multi-centric fibrosarcoma, and congenital fibrosarcoma. Generally, fibrosarcoma treatment comprises chemotherapy, radiation therapy, and surgery to remove sarcoma.
Over the last decade, the cancer prophylaxis sector in developed countries has been witnessing significant growth, due to initiatives taken by governments to educate women about early diagnosis and treatment. This has helped in preventing the progression of fibrosarcoma into aggressive or advanced stages, thereby restraining the fibrosarcoma treatment market. Increasing prevalence of fibrosarcoma, rising awareness about the disease, advancements in treatment, and availability of a variety of treatments drive the market for fibrosarcoma treatment. Readily available, inexpensive, and FDA-approved therapeutics such as ifosfamide (Ifex) and doxorubicin (Adriamycin) would be augmenting the global fibrosarcoma treatment market in the next few years. Ongoing research activities and availability of strong pipeline drugs are projected to boost the fibrosarcoma treatment market during the forecast period.
The fibrosarcoma treatment market can be classified based on type of treatment and geography. In terms of type of treatment, the fibrosarcoma treatment market has been classified into chemotherapy, radiation therapy, and surgical therapy. The chemotherapy segment comprises drugs such as doxorubicin, ifosamide, cisplatin, carboplatin, and etoposide. Generally, patients are prescribed with chemotherapy drugs in early stages and with radiation therapy and surgeries in later and severe stages. Common methods of treatment for early-stage cancer include surgery or radiation therapy combined with chemotherapy. The radiation therapy, chemotherapy, and hormone therapy are often used in combination for the treatment of advanced stages of fibrosarcoma.
Based on region, the global fibrosarcoma treatment market can be segmented into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific. Among these, North America and Europe lead the market. Rising prevalence of the disease, availability of world-class diagnosis techniques, increasing awareness about health, and growing geriatric population are factors fueling the market in these regions. High investments in R&D in the U.S. and presence of African-American population wherein the disease is more common are other factors propelling the fibrosarcoma treatment market in the U.S. Asia Pacific is projected to be a rapidly expanding market for fibrosarcoma treatment during the forecast period. Rising awareness about the disease, government support, and advanced diagnostic techniques are factors boosting the market in the region. Increased investments in research and development of immunotherapy and targeted therapies, which are creating a wide product pipeline, is a driver for the market in Asia Pacific. Brazil is estimated to account for a leading share of the fibrosarcoma treatment market in Latin America. Due to rising investments in the health care sector and considerable incidence and prevalence of fibrosarcoma in the country, the market in Brazil is expected to register a high growth rate during the forecast period. Ongoing investments and recent economic development are likely to augment the fibrosarcoma treatment market in Europe from 2017 to 2025.
Key players operating in the global fibrosarcoma treatment market are Novartis AG, AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Abbott, Astellas Pharma Inc., Bristol Myers Squibb (BMS), Bayer AG, Ipsen, Tolmar Inc., Indevus Pharmaceuticals, and Ferring Pharmaceuticals.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.